Welcome to our dedicated page for Newhydrogen SEC filings (Ticker: NEWH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Newhydrogen's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Newhydrogen's regulatory disclosures and financial reporting.
NewHydrogen, Inc. reported no revenue and a net loss of $822,996 for the three months ended March 31, 2026, wider than the $476,094 loss a year earlier. Operating expenses rose to $822,701, driven mainly by higher general and administrative and research and development spending.
Cash declined to $714,341 from $1,436,928 at December 31, 2025, and working capital fell to $751,663. The company has an accumulated deficit of $181,612,486 and discloses “substantial doubt” about its ability to continue as a going concern, expecting current working capital to cover roughly three months of operating expenses.
NewHydrogen relies heavily on external funding, including an equity financing agreement with GHS for up to $3,000,000, under which 63,431,529 shares had been issued as of March 31, 2026. Potential dilution is significant, with 565,000,000 stock options and 228,958,334 warrants outstanding, while common shares outstanding reached 789,554,228 as of May 15, 2026.
NewHydrogen, Inc. registers the resale of up to 171,568,471 shares of common stock by the selling stockholder under a prospectus filed on Form 424(b)(3). The Company will not receive proceeds from those resales.
The prospectus also discloses an Equity Financing Agreement with GHS Investments, LLC that permits the Company, at its discretion and subject to conditions, to sell up to $3,000,000 of common stock to GHS; 63,431,529 Purchase Shares have been sold to date for gross proceeds of $1,354,114. The GHS arrangement limits GHS ownership to 4.99% of outstanding shares and ties Purchase Price to a discount to market pricing; following an up-list the Purchase Price mechanics change and include a $5.00 floor.
NewHydrogen, Inc. filed a Post-Effective Amendment to its Form S-1 to register the resale of up to 171,568,471 shares of common stock held by GHS Investments, LLC. The company may receive up to $3,000,000 in aggregate gross proceeds under an Equity Financing Agreement with GHS; to date 63,431,529 Purchase Shares have been sold for gross proceeds of $1,354,114. The prospectus states the company will not receive proceeds from resales by GHS and that GHS is deemed an underwriter for resale purposes. The filing discloses a reported last sale price of $0.0361 per share on the OTCQB (April 24, 2026), an accumulated deficit of $180,184,490 through December 31, 2025, and a net loss of $2,846,943 for 2025. Management notes substantial doubt about the company’s ability to continue as a going concern without additional capital.
NewHydrogen, Inc. is a development-stage clean energy company focused on ThermoLoop™, a thermochemical process that uses heat and water to produce low-cost green hydrogen. The company reported no revenue in 2025 and a net loss of $2.85 million, driven mainly by higher general and administrative, research and development, and marketing expenses.
Cash at year-end 2025 was $1.44 million with working capital of $1.43 million, and the firm expects existing cash to fund operations for about six months, anticipating additional capital needs in the second half of 2026. Accumulated deficit reached $180.79 million, and the auditor’s report and management both note substantial doubt about the company’s ability to continue as a going concern.
NewHydrogen has two full-time employees, 768,031,041 common shares outstanding as of March 30, 2026, and an estimated non-affiliate market value of $22.42 million. The business is pre-commercial, with no backlog or government contracts, and relies on university research partnerships and equity financing to advance its hydrogen technology.
NewHydrogen, Inc. reported Q3 2025 results with no revenue and a wider year‑to‑date loss. Net loss was $1,581,894 for the nine months ended September 30, 2025, including a Q3 loss of $482,096. Operating expenses totaled $1,582,324 year to date, driven by higher general and administrative, research and development, and selling and marketing spending.
Cash was $1,306,271 at September 30, 2025, down from $2,104,521 at year‑end, after $1,413,695 used in operations. The company raised $615,445 via its equity financing agreement with GHS, issuing 25,245,680 shares and 803,536 shares for a $30,000 commitment fee. Shareholders’ equity (deficit) was $(2,111,010), and accumulated deficit reached $179,524,441. Working capital was $1,318,162. Management references going‑concern uncertainty but believes current resources support about nine months of operations. As of November 10, 2025, common shares outstanding were 759,218,392. Subsequent to quarter‑end, additional shares were issued to GHS under the financing agreement.